MX2019007984A - Apareamiento preferido de dominios de anticuerpos. - Google Patents

Apareamiento preferido de dominios de anticuerpos.

Info

Publication number
MX2019007984A
MX2019007984A MX2019007984A MX2019007984A MX2019007984A MX 2019007984 A MX2019007984 A MX 2019007984A MX 2019007984 A MX2019007984 A MX 2019007984A MX 2019007984 A MX2019007984 A MX 2019007984A MX 2019007984 A MX2019007984 A MX 2019007984A
Authority
MX
Mexico
Prior art keywords
domain
antibody
antibody domains
preferred pairing
domains
Prior art date
Application number
MX2019007984A
Other languages
English (en)
Inventor
Rüker Florian
Bönisch Maximilian
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of MX2019007984A publication Critical patent/MX2019007984A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Una molécula de unión a antígeno (ABM) que comprende un dímero LC/HC afín de una cadena ligera (LC) de anticuerpo compuesta por un dominio de anticuerpo VL y un dominio de anticuerpo CL, asociada a una cadena pesada de anticuerpo (HC) que comprende al menos un dominio de anticuerpo VH y un dominio de anticuerpo CH1, asociación que es a través del apareamiento de los dominios VL y VH y los dominios CL y CH, donde los aminoácidos en la posición 18 en el dominio CL y en la posición 26 en el dominio CH1 son de polaridad opuesta, donde la numeración es de acuerdo con la IMGT.
MX2019007984A 2017-02-02 2018-02-02 Apareamiento preferido de dominios de anticuerpos. MX2019007984A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17154388 2017-02-02
PCT/EP2018/052624 WO2018141894A1 (en) 2017-02-02 2018-02-02 Preferred pairing of antibody domains

Publications (1)

Publication Number Publication Date
MX2019007984A true MX2019007984A (es) 2019-10-15

Family

ID=57965749

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019007984A MX2019007984A (es) 2017-02-02 2018-02-02 Apareamiento preferido de dominios de anticuerpos.

Country Status (13)

Country Link
US (1) US20190352429A1 (es)
EP (1) EP3577137A1 (es)
JP (1) JP7123063B2 (es)
KR (1) KR20190113870A (es)
CN (1) CN110382537B (es)
AU (1) AU2018214208A1 (es)
BR (1) BR112019013648A2 (es)
CA (1) CA3050988A1 (es)
IL (1) IL268401A (es)
MX (1) MX2019007984A (es)
SG (1) SG11201905259SA (es)
WO (1) WO2018141894A1 (es)
ZA (1) ZA201903796B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10077298B2 (en) 2012-11-28 2018-09-18 Zymeworks Inc. Engineered immunoglobulin heavy chain-light chain pairs and uses thereof
US9914785B2 (en) 2012-11-28 2018-03-13 Zymeworks Inc. Engineered immunoglobulin heavy chain-light chain pairs and uses thereof
PT3359576T (pt) 2015-10-08 2025-03-27 Zymeworks Bc Inc Constructos de polipeptídeo de ligação a antigénio compreendendo cadeias leves capa e lambda e usos dos mesmos
WO2021067404A2 (en) * 2019-09-30 2021-04-08 Adimab, Llc Ch1 domain variants engineered for preferential light chain pairing and multispecific antibodies comprising the same
KR20230066552A (ko) * 2020-07-24 2023-05-16 에프. 호프만-라 로슈 아게 항체-다량체-융합체의 발현 방법
US20230357389A1 (en) * 2020-09-29 2023-11-09 Innovent Biologics (Suzhou) Co., Ltd. Anti-claudin18.2 and cd3 bispecific antibody and use thereof
EP4288460A4 (en) * 2021-02-05 2025-04-02 Phanes Therapeutics, Inc. BISPECIFIC ANTIBODIES WITH CHARGE PAIRS AND USES THEREOF
WO2025167974A1 (zh) * 2024-02-07 2025-08-14 上海齐鲁制药研究中心有限公司 多特异性抗体或抗原结合片段

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
AU777192B2 (en) * 1994-05-27 2004-10-07 Ariad Gene Therapeutics, Inc. Immunosuppressant target proteins
PT2314629E (pt) * 2002-07-18 2014-01-22 Merus B V Produção recombinante de misturas de anticorpos
SI1713503T1 (sl) * 2004-02-10 2013-12-31 The Regents Of The University Of Colorado, A Body Corporate Inhibicija faktorja B, alternativna komplementa pot in relevantni postopki
ES2395969T3 (es) 2006-03-24 2013-02-18 Merck Patent Gmbh Dominios de proteínas heterodiméricas genéticamente modificados
ES2395799T3 (es) 2007-07-17 2013-02-15 Merck Patent Gmbh Anticuerpos híbridos anti- integrina alfa V modificados genéticamente
CN101348475B (zh) * 2007-07-20 2011-03-30 重庆人本药物研究院 一种奥利司他合成方法、中间体化合物及其制备方法
EP2435473B1 (en) 2009-05-27 2013-10-02 F.Hoffmann-La Roche Ag Tri- or tetraspecific antibodies
AU2011325833C1 (en) * 2010-11-05 2017-07-13 Zymeworks Bc Inc. Stable heterodimeric antibody design with mutations in the Fc domain
AU2012332021B8 (en) * 2011-11-04 2017-10-12 Zymeworks Bc Inc. Stable heterodimeric antibody design with mutations in the Fc domain
JP6203838B2 (ja) * 2012-06-27 2017-09-27 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 少なくとも２つの異なる結合実体を含む、テーラーメイドの高度に選択的かつ多重特異的なターゲティング実体を選択および作製するための方法、ならびにその使用
UY35148A (es) * 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
EP2970435B1 (en) * 2013-03-15 2020-08-12 Eli Lilly and Company Methods for producing fabs and bi-specific antibodies
ES2935274T3 (es) * 2014-12-05 2023-03-03 Merck Patent Gmbh Anticuerpo con intercambio de dominios

Also Published As

Publication number Publication date
BR112019013648A2 (pt) 2020-01-21
CA3050988A1 (en) 2018-08-09
RU2019119391A3 (es) 2021-05-25
IL268401A (en) 2019-09-26
SG11201905259SA (en) 2019-08-27
CN110382537A (zh) 2019-10-25
CN110382537B (zh) 2023-07-25
EP3577137A1 (en) 2019-12-11
AU2018214208A1 (en) 2019-07-11
KR20190113870A (ko) 2019-10-08
RU2019119391A (ru) 2021-03-02
JP2020505929A (ja) 2020-02-27
ZA201903796B (en) 2022-11-30
WO2018141894A1 (en) 2018-08-09
US20190352429A1 (en) 2019-11-21
JP7123063B2 (ja) 2022-08-22

Similar Documents

Publication Publication Date Title
MX2019007984A (es) Apareamiento preferido de dominios de anticuerpos.
MA39266A (fr) Anticorps bispécifiques anti cd3epsilon et bcma
MY186351A (en) Multispecific antibodies
CO2019009076A2 (es) Anticuerpos biespecíficos de unión específica a pd1 y lag3
SA517381604B1 (ar) أجسام مضادة ديمرية غير متجانسة جديدة
ES2687282T3 (es) Anticuerpos humanizados ANTI-CD134 (OX40) y sus usos
CL2020002540A1 (es) Anticuerpos anti-hla-g y utilización de los mismos
MY192853A (en) High-affinity and aggregatively stable antibodies on the basis of variable domains vl and a derivative vhh
MY205342A (en) Bispecific 2+1 contorsbodies
CR20190434A (es) Anticuerpos anti-lag3
MX2018015592A (es) Anticuerpos inhibidores de puntos de control biespecificos.
FI4249515T3 (fi) Humanisoituja tai kimeerisiä CD3-vasta-aineita
PE20181805A1 (es) Composiciones y anticuerpos anti-tim-3
EA201790359A1 (ru) Пирролобензодиазепины и их конъюгаты, связанные дисульфидной связью с антителами
MX395074B (es) Anticuerpos anti-axl, fragmentos de anticuerpos y sus inmunoconjugados y usos de los mismos
MX2016006301A (es) Construcciones de unión a antígeno monovalente que se dirigen a egfr y/o her2, y sus usos.
AR069797A1 (es) Anticuerpos especificos bivalentes
EA201992756A3 (ru) Антитела против cd48 и их конъюгаты
MX373856B (es) Conjugados helicoidales-anticuerpo anti-helicoidal unidos covalentemente y usos de los mismos.
ZA202101258B (en) Anti-mica/b antibodies that block mica/b shedding and methods of use
MX389708B (es) Neutralizacion de moleculas de union anti-influenza y usos de las mismas.
MX2017011252A (es) ANTICUERPOS IGG MODIFICADOS QUE SE UNEN AL FACTOR DE CRECIMIENTO TRANSFORMANTE-ß1 CON ALTA AFINIDAD, AVIDEZ Y ESPECIFICIDAD.
WO2019147863A3 (en) Mica/b antibodies and methods of use
MX2022007456A (es) Dimeros scfv-fc que se unen al factor de crecimiento transformante-?1 con alta afinidad, avidez y especificidad.
CO2022018430A2 (es) Anticuerpos dirigidos a un complejo que comprende hla-i no clásico y neoantígeno y sus métodos de uso